Highly potent activation of Nrf2 by topical tricyclic bis(cyano enone): Implications for protection against UV radiation during thiopurine therapy

Cancer Prevention Research

Volumn 5, Issue 7, 2012, Pages 973-981

  Kalra, Sukirti ^a   Knatko, Elena V ^a   Zhang, Ying ^a   Honda, Tadashi ^b   Yamamoto, Masayuki ^c   Dinkova Kostova, Albena T ^a,d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b STONY BROOK UNIVERSITY   (United States)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLENIC TRICYCLIC BIS(CYANO ENONE); ANTIINFLAMMATORY AGENT; AZATHIOPRINE; GENOMIC DNA; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MERCAPTOPURINE; RADIOPROTECTIVE AGENT; TBE 31; TIOGUANINE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG EFFICACY; GENOTYPE; KERATINOCYTE; KNOCKOUT GENE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHOTOSENSITIVITY; PRIORITY JOURNAL; RADIATION PROTECTION; SKIN CELL; TRANSCRIPTION INITIATION; ULTRAVIOLET A RADIATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADMINISTRATION, TOPICAL; ANIMALS; CELLS, CULTURED; CYTOPROTECTION; CYTOSKELETAL PROTEINS; EMBRYO, MAMMALIAN; FEMALE; FIBROBLASTS; LIVER; MICE; MICE, HAIRLESS; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PHENANTHRENES; REACTIVE OXYGEN SPECIES; SKIN; THIOGUANINE; ULTRAVIOLET RAYS;

EID: 84866445766     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0041     Document Type: Article

References (48)

1. Talalay P. Chemoprotection against cancer by induction of phase 2 enzymes. Biofactors 2000;12:5-11. (Pubitemid 32107378)
2. Talalay P, De Long MJ, Prochaska HJ. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc Natl Acad Sci U S A 1988;85:8261-5.
3. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007;47:89-116.
4. Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal 2010;13:1713-48.
5. Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011;16:123-40.
6. Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 2011;85:241-72.
7. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 2005;102:4584-9. (Pubitemid 40397155)
8. Liu H, Dinkova-Kostova AT, Talalay P. Coordinate regulation of enzyme markers for infl ammation and for protection against oxidants and electrophiles. Proc Natl Acad Sci U S A 2008;105:15926-31.
9. Honda T, Rounds BV, Gribble GW, Suh N, Wang Y, Sporn MB. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1998;8:2711-4. (Pubitemid 28496657)
10. Honda T, Rounds BV, Bore L, Favaloro FGJr, Gribble GW, Suh N, et al. Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1999;9:3429-34.
11. Honda T, Rounds BV, Bore L, Finlay HJ, Favaloro FG Jr, Suh N, et al. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J Med Chem 2000;43:4233-46.
12. Favaloro FG Jr, Honda T, Honda Y, Gribble GW, Suh N, Risingsong R, et al. Design and synthesis of tricyclic compounds with enone functionalities in rings A and C: a novel class of highly active inhibitors of nitric oxide production in mouse macrophages. J Med Chem 2002;45:4801-5. (Pubitemid 35192769)
13. Honda T, Favaloro FG Jr, Janosik T, Honda Y, Suh N, Sporn MB, et al. Efficient synthesis of (-)- and (+)-tricyclic compounds with enone functionalities in rings A and C. A novel class of orally active anti-inflammatory and cancer chemopreventive agents. Org Biomol Chem 2003;1:4384-91.
14. Honda T, Sundararajan C, Yoshizawa H, Su X, Honda Y, Liby KT, et al. Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents. J Med Chem 2007;50:1731-4. (Pubitemid 46626584)
15. Honda T, Yoshizawa H, Sundararajan C, David E, Lajoie MJ, Favaloro FG Jr, et al. Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents. J Med Chem 2011;54:1762-78.
16. Liby K, Yore MM, Roebuck BD, Baumgartner KJ, Honda T, Sundararajan C, et al. A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. Cancer Res 2008;68:6727-33.
17. Dinkova-Kostova AT, Talalay P, Sharkey J, Zhang Y, Holtzclaw WD, Wang XJ, et al. An exceptionally potent inducer of cytoprotective enzymes: elucidation of the structural features that determine inducer potency and reactivity with Keap1. J Biol Chem 2010;285:33747-55.
18. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007;7:357-69. (Pubitemid 46652485)
19. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 2011;74:537-45.
20. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008;8:24-36.
21. Maddox JS, Soltani K. Risk of nonmelanoma skin cancer with azathioprine use. Inflamm Bowel Dis 2008;14:1425-3.
22. Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012;27:385-9.
23. Proby CM, Wisgerhof HC, Casabonne D, Green AC, Harwood CA, Bouwes-Bavinck JN. The epidemiology of transplant-associated keratinocyte cancers in different geographical regions. Cancer Treat Res 2009;146:75-95.
24. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002;47:1-17.
25. Hofbauer GF, Attard NR, Harwood CA, McGregor JM, Dziunycz P, Iotzova-Weiss G, et al. Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine. Am J Transplant 2012;12:218-25.
26. Ren X, Li F, Jeffs G, Zhang X, Xu YZ, Karran P. Guanine sulphinate is a major stable product of photochemical oxidation of DNA 6-thioguanine by UVA irradiation. Nucleic Acids Res 2010;38:1832-40.
27. Ren X, Xu YZ, Karran P. Photo-oxidation of 6-thioguanine by UVA: The formation of addition products with low molecular weight thiol compounds. Photochem Photobiol 2010;86:1038-45.
28. O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005;309:1871-4. (Pubitemid 41325100)
29. Montaner B, O'Donovan P, Reelfs O, Perrett CM, Zhang X, Xu YZ, et al. Reactive oxygen-mediated damage to a human DNA replication and repair protein. EMBO Rep 2007;8:1074-9. (Pubitemid 350042344)
30. Brem R, Li F, Karran P. Reactive oxygen species generated by thiopurine/UVA cause irreparable transcription-blocking DNA lesions. Nucleic Acids Res 2009;37:1951-61.
31. Gueranger Q, Kia A, Frith D, Karran P. Crosslinking of DNA repair and replication proteins to DNA in cells treated with 6-thioguanine and UVA. Nucleic Acids Res 2011;39:5057-66.
32. Lennard L, Thomas S, Harrington CI, Maddocks JL. Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol 1985;113:723-9. (Pubitemid 16186885)
33. PerrettCM, Walker SL, O'Donovan P, Warwick J, Harwood CA, Karran P, et al. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol 2008;159:198-204. (Pubitemid 351874494)
34. Warren DJ, Andersen A, Slørdal L. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. Cancer Res 1995;55:1670-4.
35. Cuffari C, Seidman EG, Latour S, Théorêt Y. Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy. Can J Physiol Pharmacol 1996;74:580-5. (Pubitemid 26341481)
36. Kalra S, Zhang Y, Knatko EV, Finlayson S, Yamamoto M, Dinkova-Kostova AT. Oral azathioprine leads to higher incorporation of 6-thioguanine in DNA of skin than liver: The protective role of the Keap1/Nrf2/ARE pathway. Cancer Prev Res 2011;4:1665-74.
37. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85. (Pubitemid 16258399)
38. Prochaska HJ, Santamaria AB. Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal Biochem 1988;169:328-36. (Pubitemid 18081406)
39. Habig WH, Jakoby WB. Glutathione S-transferases (rat and human). Methods Enzymol 1981;77:218-31.
40. Okada K, Shoda J, Taguchi K, Maher JM, Ishizaki K, Inoue Y, et al. Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxifi cation, and antioxidative stress systems in mice. Am J Physiol Gastrointest Liver Physiol 2008;295:G735-47.
41. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001;276:33747-54.
42. Wielinga PR, Reid G, Challa EE, van der Heijden I, van Deemter L, de Haas M, et al. Thiopurine metabolism and identi fication of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 2002;62:1321-31. (Pubitemid 35407456)
43. Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, et al. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 2008;68:4983-9.
44. Maher JM, Dieter MZ, Aleksunes LM, Slitt AL, Guo G, Tanaka Y, et al. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology 2007;46:1597-610. (Pubitemid 350155541)
45. Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, et al. Genetic versus chemoprotective activation of Nrf2 signaling: Overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 2009;30:1024-31.
46. Zhang Y, Ahn YH, Benjamin IJ, Honda T, Hicks RJ, Calabrese V, et al. HSF1-dependent upregulation of Hsp70 by sulfhydryl-reactive inducers of the KEAP1/NRF2/ARE pathway. Chem Biol 2011;18:1355-61.
47. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI, Kobayashi A, Yamamoto M, et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci U S A 2004;101:2040-5. (Pubitemid 38229011)
48. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004;3:115-24. (Pubitemid 38239773)